Ossianix
Leadership & Board
Roles and biographies as published on the company website.
Leadership
Frank S Walsh, PhD
Founder & CEO
Former global head of discovery at Wyeth and neurology executive at GSK, after an academic career in experimental pathology and neuroscience.
Official profile ↗
J Lynn Rutkowski, PhD
Founder & CSO
Translational-medicine experience at Wyeth, TMRC and Neuronyx, following academic neuroscience work; doctorate in pharmacology/toxicology from the University of Maryland.
Official profile ↗
Steve Moore, PhD
COO
Research and project leadership in pharma and biotech; joined Ossianix in 2012 after TMRC Dundee and earlier roles at GSK and SmithKline Beecham.
Official profile ↗
Pawel Stocki, PhD
VP Research
Joined in 2015 and leads antibody discovery and development; previously at MedImmune and Psynova. MSc from Gdańsk, PhD from Newcastle.
Official profile ↗
Board of directors
Frank S Walsh, PhD
Board Member
Former global head of discovery at Wyeth and neurology executive at GSK, after an academic career in experimental pathology and neuroscience.
Official profile ↗
Michael J Owen, PhD
Chairman
Joined the board in 2013, per the company. Co-founder of Kymab, with earlier biopharmaceutical research leadership at GSK.
Official profile ↗
Corey Goodman, PhD
Founder & Board Member
Neuroscientist and biotechnology entrepreneur with experience at Stanford and Berkeley, Pfizer and venBio.
Official profile ↗
Gregory Harriman, MD
Board Member
Physician and biomedical executive with development experience at IVAX and Centocor/J&J, and life-sciences investment and board roles.
Official profile ↗
Achievements listed refer to the individuals’ careers, not to Ossianix outcomes.